Literature DB >> 20505551

The metabotropic glutamate mGluR5 receptor agonist CHPG stimulates food intake.

Karolina Ploj1, Sara Albery-Larsdotter, Susanne Arlbrandt, Magnus B Kjaer, Pia M C Skantze, Leonard H Storlien.   

Abstract

The metabotropic glutamate receptor 5 (mGluR5) has been suggested to modulate energy balance. For example, mGluR5 antagonists inhibit food intake in rodents and mGluR5 knockout mice resist diet-induced obesity. However, nonspecific effects can reduce food intake. Thus, to further support the role of mGluR5 in feeding behaviour, we evaluated if the mGluR5 agonist (R,S)-2-chloro-5-hydroxyphenylglycine (CHPG) would induce the opposite effect, i.e. increased food intake in rats. Intracerebroventricularly injected CHPG (0.5-1.5 micromol) induced a dose-dependent stimulation of food intake (349% increase at 2 h with 1.5 micromol). The mGluR5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (10 mg/kg intraperitoneally) reduced 24 h food intake, without altering CHPG-induced feeding. These findings further support a physiologically relevant role of mGluR5 in appetite regulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20505551     DOI: 10.1097/WNR.0b013e32833b4fe7

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  10 in total

1.  A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers.

Authors:  Carolina L Haass-Koffler; Kimberly Goodyear; Victoria M Long; Harrison H Tran; Antonella Loche; Roberto Cacciaglia; Robert M Swift; Lorenzo Leggio
Journal:  Eur J Pharm Sci       Date:  2017-08-01       Impact factor: 4.384

Review 2.  Melanocortin neurons: Multiple routes to regulation of metabolism.

Authors:  Wen-Jie Shen; Ting Yao; Xingxing Kong; Kevin W Williams; Tiemin Liu
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-05-09       Impact factor: 5.187

3.  The association between eating behavior and polymorphisms in GRIN2B, GRIK3, GRIA1 and GRIN1 genes in people with type 2 diabetes mellitus.

Authors:  Olga V Kochetova; Diana S Avzaletdinova; Gulnaz F Korytina; Tatyana V Morugova; Olga E Mustafina
Journal:  Mol Biol Rep       Date:  2020-02-10       Impact factor: 2.316

Review 4.  Negative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic Window.

Authors:  Yoan Mihov; Gregor Hasler
Journal:  Int J Neuropsychopharmacol       Date:  2016-07-05       Impact factor: 5.176

5.  Novel genes involved in severe early-onset obesity revealed by rare copy number and sequence variants.

Authors:  Clara Serra-Juhé; Gabriel Á Martos-Moreno; Francesc Bou de Pieri; Raquel Flores; Juan R González; Benjamín Rodríguez-Santiago; Jesús Argente; Luis A Pérez-Jurado
Journal:  PLoS Genet       Date:  2017-05-10       Impact factor: 5.917

6.  Negative Modulation of the Metabotropic Glutamate Receptor Type 5 as a Potential Therapeutic Strategy in Obesity and Binge-Like Eating Behavior.

Authors:  Tadeu P D Oliveira; Bruno D C Gonçalves; Bruna S Oliveira; Antonio Carlos P de Oliveira; Helton J Reis; Claudia N Ferreira; Daniele C Aguiar; Aline S de Miranda; Fabiola M Ribeiro; Erica M L Vieira; András Palotás; Luciene B Vieira
Journal:  Front Neurosci       Date:  2021-02-10       Impact factor: 4.677

7.  Glutamate and GABA in Appetite Regulation.

Authors:  Teresa C Delgado
Journal:  Front Endocrinol (Lausanne)       Date:  2013-08-15       Impact factor: 5.555

8.  Microbiome Profiling Reveals Gut Dysbiosis in the Metabotropic Glutamate Receptor 5 Knockout Mouse Model of Schizophrenia.

Authors:  Carolina Gubert; Geraldine Kong; Volkan Uzungil; Ariel M Zeleznikow-Johnston; Emma L Burrows; Thibault Renoir; Anthony J Hannan
Journal:  Front Cell Dev Biol       Date:  2020-10-29

9.  The selective blockade of metabotropic glutamate receptor-5 attenuates fat accumulation in an <em>in vitro</em> model of benign steatosis.

Authors:  Andrea Ferrigno; Clarissa Berardo; Laura Giuseppina Di Pasqua; Marta Cagna; Veronica Siciliano; Plinio Richelmi; Mariapia Vairetti
Journal:  Eur J Histochem       Date:  2020-11-10       Impact factor: 3.188

10.  Polaprezinc (Zinc-L-Carnosine Complex) as an Add-on Therapy for Binge Eating Disorder and Bulimia Nervosa, and the Possible Involvement of Zinc Deficiency in These Conditions: A Pilot Study.

Authors:  Kensaku Sakae; Machi Suka; Hiroyuki Yanagisawa
Journal:  J Clin Psychopharmacol       Date:  2020 Nov/Dec       Impact factor: 3.118

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.